ANTIEPILEPTIC DRUGS MARKET ANALYSIS

Market News

• On January 12, 2023, IAMA Therapeutics, a pre-clinical stage pharmaceutical company, and PsychoGenics Inc., a leader in AI-enabled phenotypic drug discovery, announced that both companies had signed an agreement to identify the efficacy of novel drug candidates in pre-clinical animal models of Dravet syndrome. Dravet syndrome is a rare type of intractable epilepsy that develops in childhood and progresses with increasing morbidity that has a substantial impact on individuals throughout their lives.
• In July 2022, Marinus Pharmaceuticals, Inc., a pharmaceutical company that is dedicated to the development of novel therapeutics for seizure disorders, announced the commercial launch of ZTALMY (ganaxolone) oral suspension, CV, in the U.S. for the treatment of seizures associated with CDKL5 deficiency disorder (CDD) in patients of two years of age and older. The U.S. Food and Drug Administration authorized ZTALMY in March 2022, based on findings from the Phase 3 Marigold double-blind placebo-controlled trial of 101 patients with CDD.
• In June 2022, Lipocine Inc., a biopharmaceutical company that focuses on developing novel products for neuroendocrine and metabolic disorders, presented "LPCN 2101: An Endogenous Neuroactive Steroid for Epilepsy" at the Epilepsy Foundation Pipeline Conference in 2022 at California, U.S  Every two years, the conference brings together decision-makers in the fields of epilepsy treatment, therapeutic innovation, and development, displaying the most recent breakthroughs in the epileptic pipeline.